- Home
- EBON vs ADAP Comparison
EBON vs ADAP Comparison
Compare EBON & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBON
- ADAP
- Stock Information
- Founded
- EBON 2010
- ADAP 2008
- Country
- EBON China
- ADAP United Kingdom
- Employees
- EBON N/A
- ADAP N/A
- Industry
- EBON Semiconductors
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- EBON Technology
- ADAP Health Care
- Exchange
- EBON Nasdaq
- ADAP Nasdaq
- Market Cap
- EBON 25.3M
- ADAP 21.3M
- IPO Year
- EBON 2020
- ADAP 2015
- Fundamental
- Price
- EBON $4.08
- ADAP $0.05
- Analyst Decision
- EBON
- ADAP Hold
- Analyst Count
- EBON 0
- ADAP 6
- Target Price
- EBON N/A
- ADAP $1.02
- AVG Volume (30 Days)
- EBON 11.9K
- ADAP 62.2M
- Earning Date
- EBON 08-15-2025
- ADAP 08-13-2025
- Dividend Yield
- EBON N/A
- ADAP N/A
- EPS Growth
- EBON N/A
- ADAP N/A
- EPS
- EBON N/A
- ADAP N/A
- Revenue
- EBON $7,337,066.00
- ADAP $65,084,999.00
- Revenue This Year
- EBON N/A
- ADAP N/A
- Revenue Next Year
- EBON N/A
- ADAP $52.35
- P/E Ratio
- EBON N/A
- ADAP N/A
- Revenue Growth
- EBON 104.28
- ADAP N/A
- 52 Week Low
- EBON $3.00
- ADAP $0.05
- 52 Week High
- EBON $10.94
- ADAP $1.32
- Technical
- Relative Strength Index (RSI)
- EBON 50.20
- ADAP 31.08
- Support Level
- EBON $3.71
- ADAP $0.06
- Resistance Level
- EBON $4.60
- ADAP $0.07
- Average True Range (ATR)
- EBON 0.27
- ADAP 0.01
- MACD
- EBON 0.03
- ADAP 0.01
- Stochastic Oscillator
- EBON 41.81
- ADAP 0.00
About EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.